Sanjay Kumar Jain, Rajesh Kumar Jain
firstname.lastname@example.org , email@example.com
Sanjay Kumar Jain1, Rajesh Kumar Jain2
1Ph.D Scholar, Nirma University, Ahmedabad, Gujarat, India.
2Professor- Operations Management, Nirma University, Ahmedabad, Gujarat.
Volume - 14,
Issue - 2,
Year - 2021
Pharmaceutical industry manufactures various type of pharmaceutical products like drug substances, drug products, medical devices and bio-pharmaceuticals for the treatment of diseased persons, hence product quality and patient safety is paramount vital. This is very reason that this industry is highly regulated industry. In spite of stringent regulations, there is increased number of warning letters which is a matter of concern for the manufacturers, drug authority and society. As a part of this study, 85 warning letters (www.fda.gov) issued to the drug substance and drug product manufacturers for three years (2014 to 2016) were reviewed. The qualitative and quantitative study was undertaken as a part of this study. In qualitative study, six experienced pharma professionals were interacted with an objective to know the reasons for issuance of warning letters. In quantitative study, an instrument was developed to measures the Practices regarding quality system, data integrity management practice, laboratory control and manufacturing control management practices. Instrument consisting of 64 items was circulated to various pharma professionals working in the pharmaceutical companies across the globe. Data collected from qualitative study were compiled and concluded that poor quality system, lack of management overview, right quality culture in the organization, incorrect attitude of employees towards quality and data integrity are the major reasons for non-compliances resulting into issuance of warning letter. Data collected from 317 responsdents was statistically analysed and it revealed the differences in the Good Manufacturing Practices (GMP) among the pharma drug manufacturer of India and Abroad. It also revealed that GMP practices within India are same. There is difference in GMP practices in large and small organizations with respect to based on annual turnover and employee strength. Issuance of warning letter and import alert has significant impact on continuity of the business as there is loss of trust among partners, regulators and customers. There is loss of business opportunity and manufacturer has to spend time and money to revive the quality system meeting Agency’s expectations. There is need for Paradigm shift in quality culture and transparency. Quality, compliance and integrity are the pillars for any pharmaceutical organization to be successful.
Cite this article:
Sanjay Kumar Jain, Rajesh Kumar Jain. A Study of Regulatory Agencies Inspected Global Drug Manufacturers. Research J. Pharm. and Tech. 2021; 14(2):1008-1016. doi: 10.5958/0974-360X.2021.00180.3
Sanjay Kumar Jain, Rajesh Kumar Jain. A Study of Regulatory Agencies Inspected Global Drug Manufacturers. Research J. Pharm. and Tech. 2021; 14(2):1008-1016. doi: 10.5958/0974-360X.2021.00180.3 Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2021-14-2-76
1. Jain Sanjay Kumar, and Jain Rajesh Kumar (2018), Review Of FDA Warning Letters To Pharmaceuticals: Cause And Effect Analysis. Research J. Pharm. and Tech. 11(7), 3219-3226
2. Jain Sanjay Kumar, and Jain Rajesh Kumar (2017), Evolution of GMP in pharmaceutical Industry. Research J. Pharm. and Tech. 10(2), 501-506
3. https://www.ibef.org/industry/pharmaceutical-india.aspx (Accessed on 26 Feb 2019)
4. Gough H.F., (1989),"Quality Assurance – Lessons to be Learned from the Pharmaceutical Industry", British Food Journal, 91(9), 10-12
5. Goodwin Paige S. and Jacobs Kevin T., (2013)," A Primer on the admissibility of FDA Warning Letters", Defense Counsel Journal, 36-45
6. Yu Lawrence X., and Woodcock Janet (2015), “FDA pharmaceutical quality oversight”, International Journal of Pharmaceutics, 491, 2-7
7. Ananth L, Gurbani N K., Kumar S, and Gujavarti B (2018), “A retrospective study of Warning Letters issued by US FDA over 2015-2017”, International Journal of Drug Regulatory Affairs; 2018; 6(2); 48-53
8. Khoja SS, Khoja S, Chauhan PH, and Khoja FS (2016) ; “A review on USFDA warning letter and violation observed in Pharmaceutical Industry”, Pharma Tutor; 4(12);33-36
9. Unger Barbara (2019), An Analysis Of FDA FY2018 Drug GMP Warning Letters, (https://www.pharmaceuticalonline.com/doc/an-analysis-of-fda-fy-drug-gmp-warning-letters-0003)
10. Patel DS (2012), FDA Warning Letter Analysis: A Tool for GMP Compliance. Int J Pharm Sci Res. 3(12); 4592-4603.
11. Hair, J.F. Jr., Anderson, R.E., Tatham, R. L. and Black W.C. (1998). Multivariate Data Analysis, New Jersy: Prentice-Hall.